Back to today’s briefing

Story perspectives

Bristol Myers’ Iberdomide Shows Promise in Phase 3 Study

9/24/2025

42 5

Summary

Story summary

Iberdomide from Bristol Myers Squibb shows Phase 3 improvement vs standard therapy in EXCALIBER-RRMM.
Interim analysis shows higher rates of minimal residual disease negativity.
The EXCALIBER-RRMM study will continue to assess progression-free and overall survival.
The safety profile matches prior studies.
Analysts project $1.3 billion in annual sales by 2035, and Bristol Myers Squibb will submit findings to health regulators.

1 of 1

Story summary

Iberdomide from Bristol Myers Squibb shows Phase 3 improvement vs standard therapy in EXCALIBER-RRMM.
Interim analysis shows higher rates of minimal residual disease negativity.
The EXCALIBER-RRMM study will continue to assess progression-free and overall survival.
The safety profile matches prior studies.
Analysts project $1.3 billion in annual sales by 2035, and Bristol Myers Squibb will submit findings to health regulators.